Clearside Biomedical’s (CLSD) “Buy” Rating Reiterated at HC Wainwright

Clearside Biomedical (NASDAQ:CLSD)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $6.00 target price on the stock.

Other analysts also recently issued research reports about the stock. Needham & Company LLC reissued a “buy” rating and set a $6.00 target price on shares of Clearside Biomedical in a research report on Thursday. StockNews.com upgraded Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $6.00 target price on shares of Clearside Biomedical in a report on Friday, November 15th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Clearside Biomedical has a consensus rating of “Moderate Buy” and an average price target of $5.33.

Clearside Biomedical Price Performance

Clearside Biomedical stock traded up $0.11 during midday trading on Thursday, reaching $0.96. The company’s stock had a trading volume of 804,558 shares, compared to its average volume of 399,340. Clearside Biomedical has a 52-week low of $0.77 and a 52-week high of $2.12. The stock has a market capitalization of $72.81 million, a P/E ratio of -2.13 and a beta of 2.10. The stock’s 50-day simple moving average is $0.96 and its 200-day simple moving average is $1.06.

Hedge Funds Weigh In On Clearside Biomedical

Several institutional investors and hedge funds have recently modified their holdings of CLSD. Investor s Fiduciary Advisor Network LLC purchased a new position in Clearside Biomedical in the 4th quarter valued at $32,000. Northern Trust Corp raised its position in shares of Clearside Biomedical by 24.0% in the fourth quarter. Northern Trust Corp now owns 165,499 shares of the company’s stock valued at $157,000 after buying an additional 32,048 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Clearside Biomedical by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 764,058 shares of the company’s stock worth $726,000 after buying an additional 32,672 shares in the last quarter. Finally, Johnson & Johnson acquired a new position in Clearside Biomedical during the third quarter worth about $105,000. Hedge funds and other institutional investors own 18.75% of the company’s stock.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.